Pfizer CEO Ian Read says the company will return to “business as normal” and continue with scheduled price increases at the start of 2019, despite pressure from President Donald Trump, FirstWord Pharma reports.
The company in July deferred price hikes after Trump chided the drugmaker, and other pharmaceutical companies, and indicated then that the freeze was impermanent.
“I don’t think the pricing situation has changed,” Read said during Pfizer’s third-quarter earnings call. “I have, at this moment, no different view about how we will take price increases as we did last year.”
Read took aim at the Trump administration’s recent proposal to pull down prices for Medicare Part B drugs in line with a global average.